News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt. August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Aug 2024 Six epigenetics companies making strides in 2024 In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry. August 2, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2024 European regulators reject Alzheimer’s drug Leqembi: is it downhill from here? European regulators have now refused to market the Alzheimer’s drug Leqembi after it was approved by the FDA last year. August 1, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2024 The future of inflammatory bowel disease treatment: what is on the horizon? Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut. July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market. July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Jul 2024 Lenacapavir: Can Gilead’s drug end the HIV pandemic? Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial. July 18, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2024 Biotech’s battle against skeletal dysplasia: Ray of hope for children with rare genetic disorder As treatments for skeletal dysplasia are intended to alleviate painful symptoms, two drugs are battling out in the clinic to prove their effectiveness. July 10, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2024 MASH candidates make a splash after first drug approval The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients. June 19, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 13 Jun 2024 From AI to telemedicine: Transforming clinical trial recruitment in 2024 Delve into the evolution of clinical trial recruitment in the recent years, with decentralized and virtual trials gaining traction. June 13, 2024 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 Jun 2024 Eight companies tackling cancer with allogeneic cell therapy in 2024 Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In allogeneic cell therapy, healthy donor cells are harvested, processed, and then infused into the patient. These donor cells can differentiate into various […] June 13, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 10 Jun 2024 ASCO 2024: The latest advances in oncology clinical trials Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024. June 10, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 6 Jun 2024 CRISPR: A promising path to treating blindness Rigorous research, which has been going on for more than a decade now, suggests that CRISPR could treat genetic diseases including blindness. June 6, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email